Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Agilent, SRI Sign Licensing Deal

By Drug Discovery Trends Editor | December 10, 2012

Agilent Technologies Inc. and SRI International announced they have signed a licensing agreement to offer laboratory research customers a package that combines Agilent’s latest release of GeneSpring GX, GeneSpring NGS, Mass Profiler Professional and Pathway Architect version 12.5 with SRI International’s complete BioCyc Pathway Database Collection. The integrated package will allow scientists to access, combine, visualize and analyze biological data sets across multiple “omics” experiments (genomics, transcriptomics, proteomics and metabolomics).

“We are pleased to join forces with SRI to provide this advanced product offering,” said Nick Roelofs, president of Agilent’s Life Sciences Group. “By combining SRI’s rich BioCyc pathway content with our fully-integrated laboratory technologies, we are providing researchers with a complete solution for designing more informed experiments, free of the cumbersome technical challenges of traditional multi-omics research. We chose to work with SRI because of the company’s breadth of coverage of organisms and excellent curation.”

The new software package will enable researchers to display biological pathway data generated by Agilent’s suite of instruments, software and reagents. Agilent solutions include microarrays and next-generation sequencing technology, as well as LC/MS, GC/MS, ICP/MS and NMR systems. Agilent is the sole global provider of world-class instruments, consumables and software for all four “omics” disciplines.

“SRI’s databases in the BioCyc Pathway collection will offer Agilent customers the high level of curation needed to accurately interpret their large-scale datasets,” said Peter Karp, Ph.D., director of the Bioinformatics Research Group at SRI International. “Our EcoCyc and MetaCyc databases have been curated from 23,000 and 35,000 publications, respectively. Along with other BioCyc databases, they help speed research in myriad domains, including biofuels, agroscience, pharmaceuticals and consumer products.”

SRI’s BioCyc is a collection of 2,038 Pathway/Genome Databases including 497 complete bacterial genomes from the Human Genome Microbiome Project. Each of the databases in the collection describes the genome and metabolic pathways of a single organism. SRI continues to expand the BioCyc collection with new types of data, curation, genomes and associated pathway predictions.

“Researchers are excited about the extraordinary capabilities they will have with this pathway-driven technology,” said Steven Fischer, Agilent’s marketing manager for metabolomics and proteomics. “Some of them, for example, may be doing genomics experiments and then realize that their next step should really be a metabolomics experiment. Either way, Agilent’s comprehensive suite of integrated technologies provides the hardware, software and consumables required to complete multiple cycles of experiments in multiple disciplines. As each experiment informs the next, they can quickly redesign, collect, measure and analyze new sets of data at a much faster rate than ever before.”

Date: December 10, 2012
Source: Agilent Technologies Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50